Institute stops trial on Revatio for sickle cell disease

07/29/2009 | Wall Street Journal, The

The National Heart, Lung and Blood Institute halted a study on Revatio, a drug that contains the key ingredient in Viagra, in patients with sickle cell disease because of safety issues. The study indicated a significantly higher risk of serious side effects in patients taking Revatio compared with those on placebo.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD